Final outcomes of the SOFT and TEXT phase III trials in premenopausal hormone receptor-positive early breast cancer
{{output}}
Background: The SOFT trial found adding ovarian function suppression (OFS) to tamoxifen (T) reduced breast cancer recurrence, and exemestane (E)+OFS further reduced recurrence. SOFT and TEXT combined analysis showed a significant... ...
